On Paxlovid rebound. 
In our prospective trial, it occurred in 14% vs 9% in controls, far less than anticipated, but more than Pfizer's trial https://nytimes.com/2023/09/26/well/live/covid-paxlovid-rebound.html?searchResultPosition=1

https://media.mstdn.social/media_attachments/files/111/171/926/262/732/741/original/6617803d58d2ce0e.png